Echocardiographic measures of left ventricular (LV) hypertrophy (LVH), and systolic and diastolic dysfunction are strong predictors of cardiovascular morbidity and mortality. [1] [2] [3] [4] [5] A number of risk factors for LVH, particularly hypertension, are known to be prevalent in African Americans. It is clear that the disproportionate number of individuals with changes in LV mass, and systolic and diastolic dysfunction in the African-American community cannot be completely explained by established risk factors alone and may be due to novel or genetic factors. 6 The role that genetics play in influencing echocardiographic traits in African Americans has not been extensively characterized.
Background
Much of the interindividual variation in left ventricular (LV) structure and function is unexplained by established risk factors and may be due to novel or genetic factors. We used pedigree information from 454 tandem markers across the genome to estimate the heritability and linkage of various echocardiographic measures of LV structure and function in a cohort of african-american hypertensive siblings.
Methods
LV mass was calculated according to the american society of Echocardiography (asE) simplified cubed equation and indexed to height 2.7 . Fractional shortening (Fs) was calculated as the percent change in the internal diameter between diastole and systole. Ejection fraction (EF) was calculated from ventricular diameters. Peak mitral early and late diastolic filling velocities were measured from the transmitral pulsed Doppler profile. the maximum-likelihood heritability estimate for each phenotype was obtained using a variance components method. Linkage analyses were performed using the multipoint variance components-based approach. results there was moderate heritability for LV mass index (34%), interventricular septal thickness (29%), diastolic diameter (42%), EF (40%), Fs (39%), and mitral early and late diastolic filling velocities (37 and 45%, respectively). the greatest evidence of genetic linkage was observed for LV mass index on chromosome 3 (logarithm of odds (LOD) score = 2.38), LV EF on chromosome 12 (LOD score = 2.39), and mitral E-wave velocity (MVE) on chromosome 19 (LOD score = 2.69).
conclusions
In this african-american cohort of hypertensive siblings, theoriginal contributions
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the Atherosclerosis Risk in Communities study. 8 Inclusion was restricted to probands in a sibship with ≥2 individuals with essential hypertension (systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg on the second and third clinic visit) diagnosed prior to age 60 who were willing to be recruited. Those index sibpairs with possible secondary hypertension (including sibpairs with previously diagnosed kidney disease (defined by serum creatinine level >2 mg/dl)) were excluded. The study was approved by the University of Mississippi Medical Center Institutional Review Board, and all participants gave written informed consent.
Of the 1,482 participants who underwent echocardiography, 74 were excluded because of self-reported prior myocardial infarction, leaving 1,408 participants included in the study population.
Clinical covariates. Body mass index (BMI) was defined as the fasting weight in kilograms divided by height in meters squared. Seated systolic and diastolic BP were measured three times, 2 min apart by trained technicians using a random-zero sphygmomanometer after a 5-min rest; an average of the second and third readings was used. Hypertension was defined based on JNC-7 guidelines (systolic ≥140 mm Hg or diastolic ≥90 mm Hg, or reported use of antihypertensive medications within 2 weeks prior to the visit). 9 Diabetes was defined as fasting serum glucose of ≥126 mg/dl, random serum glucose ≥200 mg/dl, use of diabetic medications within 2 weeks of the clinic visit, or history of physician-diagnosed diabetes.
Echocardiographic methods. During the second field examination, participants in the Jackson cohort were examined by 2-dimensional, M-mode, and Doppler echocardiography using an Acuson 128XP echo machine (Acuson, Mountain View, CA). Readings were performed at the New York Presbyterian Hospital-Weill Cornell Medical Center and verified by a single highly experienced investigator (R.B.D.). Nine LV phenotypes were studied: LV mass index, LV internal diastolic diameter, interventricular septal wall thickness, posterior wall thickness, relative wall thickness, fractional shortening (FS), ejection fraction (EF), mitral A-wave velocity, and mitral E-wave velocity (MVE). LV internal diameter, interventricular septal thickness, and posterior wall thickness were measured at end diastole and end systole according to recommendations of the American Society of Echocardiography (ASE) in up to three cardiac cycles. 10 LV mass index was calculated according to the ASE simplified cubed equation and indexed to height 2.7 . LVH was defined as indexed LV mass ≥51.0. Relative wall thickness was calculated as 2 × posterior wall thickness/LV internal diastolic diameter. FS was calculated as the percent change in the LV internal diameter between diastole and systole. EF was calculated from LV diastolic and systolic diameters. Doppler transmitral inflow was assessed in the projection in which peak flow velocity was maximal. Peak early MVE and late mitral A-wave velocity were measured from the transmitral pulsed Doppler spectral profile. Heart rate was measured simultaneously.
Genotyping methods. Genotype and phenotype data were obtained for 1,261 non-Hispanic African Americans (905 females and 356 males) in 550 sibships. There were 215 half-sib and 1,028 full-sib pairs. Genotyping of 454 highly polymorphic microsatellite marker loci located on the 22 human autosomes (from CHLC/Weber screening set 9.0) was performed at the Mammalian Genotyping Center of the Marshfield Medical Research Foundation (http://research.marshfieldclinic.org/ genetics). Details of the marker genotyping and validation are reported elsewhere. 11 Statistical analysis. All phenotyped individuals were used for the regression modeling, regardless of availability of genotype measures. Data for clinical and echocardiographic characteristics of study participants are presented as mean ± s.d. for continuous variables and percentages for categorical variables. Two-sided P < 0.05 was used as the cut-point to assess statistical significance. Because of skewing of the LV phenotype distributions, all values were log-transformed except for FS and EF that were squared. For each LV phenotype (dependent variable), sex-specific covariate-adjusted stepwise linear regression models were run (with age and age 2 forced in and other covariates allowed to remain in the model if P < 0.05) and partial R 2 values examined to assess the contribution of each significant covariate to phenotype variability; model residuals for men and women were then pooled for genetic analyses. The following covariates were retained, by phenotype: (i) For LV mass index, LV internal diameter, interventricular septal and posterior wall thicknesses, relative wall thickness: age, age 2 , BMI, stroke volume, systolic BP, and diabetes; (ii) For FS and EF: age, age 2 , stroke volume, BMI, and heart rate; and (iii) For mitral A-wave velocity and MVE: age, age 2 , BMI, stroke volume, systolic BP, and heart rate. All analyses were conducted with SAS version 9.2 (SAS Institute, Cary, NC).
The maximum-likelihood heritability estimate for each phenotype was obtained using variance components-based methods as implemented in the SAGE 12 and MERLIN 13 computer programs. Quantitative trait locus linkage analysis was performed using the multipoint variance componentsbased approach as implemented using MERLIN. 14 In variance components linkage analysis, the variance of a trait is decomposed into locus-specific effects determined by the identity-by-descent relationships (additive quantitative trait locus variance), the residual additive genetic effects (additive polygenic variance) and individual specific random environmental effects (random environmental variance). 13 The null hypothesis was that the additive quantitative trait locus variance equals zero (no linkage), and this was tested by comparing the likelihood of the restricted model with that of a model in which the additive quantitative trait locus variance was estimated. The difference between the 2 log likelihoods produces a logarithm of odds (LOD) score. Twice the difference between the 2 log likelihoods of these models yields a test statistic that is asymptotically distributed as a 50:50 mixture of a χ 2 variable and a point mass at zero. The one-unit original contributions
LOD support intervals were obtained by identifying the peaks of the maximum LOD score on the plot of the multipoint results, dropping down one LOD unit and finding the chromosomal region defined by the shoulders of the curve. 15 A LOD score ≥3.3 was taken as statistically significant evidence of linkage, and a LOD score ≥1.9 but <3.3 as evidence suggestive of linkage. 16 
results
The mean age of the study population was 72.9 years (s.d., 9.4 years), 72% were female, 13% were current smokers, 37% had diabetes or impaired fasting glucose, 70% were on antihypertensive medications, and the mean systolic and diastolic BPs were 138 (s.d., 21) mm Hg and 79 (s.d., 11) mm Hg, respectively. Twelve percent had LVH. Clinical characteristics of the study population by the presence or absence of LVH are presented in Table 1 . The group with LVH was older, had a higher percentage of diabetics, and had higher mean values for BMI and systolic BP, and lower mean values for total and highdensity lipoprotein-cholesterol.
Multivariable-adjusted heritability estimates for echocardiographically derived variables of interest are shown in Table 2 . Heritability estimates from SAGE and MERLIN were similar for echocardiographic measures of LV structure and both systolic and diastolic function. There was evidence for a moderate degree of heritability for LV mass index (34 and 33%, respectively), interventricular septal wall thickness (29 and 30%, respectively), LV diastolic diameter (42 and 39%, respectively), LV EF (40 and 42%, respectively), FS (39 and 40%, respectively), and MVE (37 and 38%, respectively) and mitral A-(45% for both SAGE and MERLIN) wave velocity.
Peak LOD scores for the genome scan on all 22 autosomes generated by the multipoint variance components-based linkage analyses are shown in Table 3 . Figure 1 shows the log odds peaks >1.30 among the 22 autosomes for each of the echocardiographic phenotypes. The best evidence of genetic linkage was for LV mass index on chromosome 3 (LOD score of 2.38 at 225 cM), LV EF on chromosome 12 (LOD score = 2.69 at 164 cM), and MVE on chromosome 19 (LOD score = 2.69 at 10 cM). The 1-LOD for the top signals identified on chromosome 3 is 219 cM, q-terminal; for chromosome 12 is 153 cM, q-terminal; and for chromosome 19 is 45 cM, p-terminal, respectively. Multivariable-adjusted model includes the following: (i) For left ventricular mass index, internal diameter, interventricular septum wall thickness, posterior wall thickness, and relative wall thickness: age, age 2 , body mass index, stroke volume, systolic blood pressure, and diabetes; (ii) For fractional shortening and ejection fraction: age, age 2 , stroke volume, body mass index, and heart rate; and (iii) For mitral early and late diastolic filling velocities: age, age 2 , body mass index, stroke volume, systolic blood pressure, and heart rate. LOD, logarithm of odds.
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We report evidence suggestive of genetic linkage in a cohort of African-American hypertensive sibships for LV mass index on chromosome 3, for LV EF on chromosome 12, and for MVE on chromosome 19. These findings are consistent with previous studies of racially mixed populations that found significant genetic associations with echocardiographic LV structure and function. 1, [17] [18] [19] [20] Our findings suggest a need for further analysis using genome-wide association studies in hypertensive African Americans to look for specific genes influencing LV mass, and systolic and diastolic function in this group. 19 Our heritability estimates suggest that the LV structure parameters that have the greatest genetic component include LV internal diameter, LV systolic function, and LV diastolic function. It can be speculated that genetic pathways are more related to increased LV cavity size and affect function, whereas pathways related to increased wall thickness are more influenced by environmental factors such as BP and BMI.
Some previous studies support our finding suggesting a potential genetic linkage for LV mass on chromosome 3. A gene that codes for protein phosphatase 1 (PP1), regulatory inhibitor subunit 2, is located under our linkage signal and is a candidate for a potential genetic contribution to LV mass. 21 PP1 counterbalances the phosphorylation of protein kinase A phospholamban in the sarcoplasmic recticulum in cardiac myocytes affecting calcium cycling. Sarcoplasmic recticulum calcium cycling has an impact on cellular contractility and myocyte proliferation and hypertrophy. PP1 is an isotype in cardiomyocytes that is overactivated in the cytosol in diseased hearts. Hyperactive PP1 has been thought to be a maladaptive original contributions
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mechanism that occurs in conjunction with altered protein kinase A signaling during heart failure progression. Inhibition of PP1 activity may be a potential treatment in the management of cardiac remodeling and heart failure. We found evidence for genetic linkage of the MVE, a parameter of diastolic function, on chromosome 19 at 10 cM. A gene coding for guanine nucleotide-binding protein α-11 (GNA-11) is located near this peak and may be responsible for genetic linkage with diastolic function. 22, 23 GNA-11 is a G-protein that is part of the calcium signaling pathway that affects both myocyte hypertrophy and contractility. This cytosolic protein interacts with G-protein receptors on the membranes of cardiac myocytes and results in the activation of protein kinase C that is a mediator of myocyte hypertrophy. GNA-11 also activates cytosolic dystrophin-associated glycoprotein (DAG) and inositol trisphosphate (IP3). DAG and IP3 affect the availability of calcium and oxygen in the sarcoplasmic reticulum of the myocyte mitochondria influencing the action of troponin C and myosin light chain kinase that affects myocyte contractility and metabolism.
Our finding suggesting genetic linkage for LV EF on chromosome 12 at 164 cM supports further investigation of the gene solute carrier family 15, member 4 that has been implicated in diabetes. This gene may be linked to LV EF through metabolic mechanisms where mediators, effectors, and targets lead to a diabetic cardiomyopathy. 24 Hyperglycemia and hyperinsulinemia influence cardiac contractility through interactions involving calcium signaling in the cardiac myocyte. Specifically, hyperglycemia increases the activity of small G-protein subfamilies that in turn increase protein kinase C in the mitochondria of myocytes and thus affect contractile proteins. Hyperinsulinemia influences a different set of small G-proteins by increasing mitogen-activated protein kinase. The net effect of increasing mitogen-activated protein kinase activity is an increase in protein synthesis and myocyte hypertrophy that over time may affect EF.
Additionally, relatively close to the linkage signal for LV EF on chromosome 12 is a gene located at 120 cM that code for human myosin light chain-2. This protein is involved in regulation of myosin adenosine triphosphatase activity in smooth muscle. An increase in ventricular expression of this protein during myocardial hypertrophy has been noted in cardiac patients. 25 Linkage studies are well suited for locating regions with large genetic effects but may not be as well suited for identifying small genetic effects. Genome-wide association analysis that is now available can better assess for genes with small genetic effects; however, sample size and multiple testing are among potential problems that have to be addressed in using that method. Particularly for this linkage study, the sample size and density of tandem markers may render this method underpowered for identifying regions of linkage across certain portions of the genome. The ability of this method to account for potential gene-gene and gene-environmental interaction is also limited. Finally, our study population consists of hypertensive African Americans, and our findings may not be generalizable to other populations.
